MedCallyLooking up the FDA label…
Looking up the FDA label…
Dihydropyridine Calcium Channel Blocker
Also sold as Cleviprex
Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Advise patients with underlying hypertension that they require continued follow up for their medical condition, and, if applicable, encourage patients to continue taking their oral antihypertensive medication(s) as directed. Advise patients to contact a healthcare professional immediately for any of the following signs of a new hypertensive emergency: neurological symptoms, visual changes, or evidence of congestive heart failure. Manufactured by: Fresenius Kabi Austria GmbH, Graz, Austria Marketed by: The Medicines Company Parsippany, New Jersey 07054 For information call: 888-977-MDCO US Patent 5,856,346 US Patent 5,739,152 TMC [PN 1220-3 (November 08, 2013)] M088834/04 USA
The following risk is discussed elsewhere in the labeling: Hypotension and Reflex Tachycardia Most common adverse reactions (>2%) are headache, nausea, and vomiting. To report SUSPECTED ADVERSE REACTIONS, contact The Medicines Company at 1-888-977-MDCO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Cleviprex clinical development included 19 studies, with 99 healthy subjects and 1307 hypertensive patients who received at least one dose of clevidipine (1406 total exposures). Clevidip…
Having one of these?
A doctor will tell you whether it matters and what to do about it. Written answer, a week of free follow-ups.
Ask a doctor — $19.99Cleviprex is contraindicated in patients with: Allergy to soy or eggs Defective lipid metabolism Severe aortic stenosis 4.1 Known Allergy Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. 4.2 Defective Lipid Metabolism Cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. 4.3 Severe Aortic Stenosis Cleviprex is contraindicated in…
For intravenous use: Cleviprex is intended for intravenous use. Titrate Cleviprex to achieve the desired blood pressure reduction. Individualize dosage depending on the blood pressure response of the patient and the goal blood pressure. Monitoring: Monitor blood pressure and heart rate during infusion, and until vital signs stabilize. Initial dose: Initiate intravenous infusion of Cleviprex at 1- 2 mg/hour. Dose titration: Double the dose at short (90 second) intervals initially. As the blood pressure approaches go…
No clinical drug interaction studies were conducted. Clevidipine and its major dihydropyridine metabolite do not have the potential for blocking or inducing any CYP enzyme. At clinically relevant concentrations, clevidipine and its metabolites do not inhibit or induce any CYP450 enzymes. The potential of clevidipine to interact with other drugs is low.
Taking something else alongside it?
Interaction warnings are written per drug, not for your particular combination. A doctor can check yours.
Ask about my combinationSame medicine, sold as
Works in a similar way — dihydropyridine derivatives
These are different medicines in the same family, not swaps for each other. Which one suits you is a prescribing decision.